Treating gynecological malignancies with deployable implants

Patent metadata

Field	Value
Publication number	US-11844857-B2
Application number	US-202016875356-A
Country	US
Kind code	B2
Filing date	May 15, 2020
Priority date	Jun 27, 2019
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

A method of treating a gynecological malignancy includes introducing an implant within a uterus of a patient and positioning the implant adjacent to an endometrium of the uterus to enable a bioactive agent supported on the implant to treat the gynecological malignancy. The implant may be one or more deployable implants including a balloon, an IUD, a stent, or combinations thereof. Such implants may be introduced by one or more surgical instruments.

First claim

What is claimed is:

1. A method of treating a gynecological malignancy, the method including:
introducing an implant adjacent to an endometrium within a uterus of a patient utilizing a surgical instrument, the implant including:
a bioactive agent proximate the outer surface of the implant and configured for treatment of a gynecological malignancy; and
a plurality of channels defined within the outer surface of the implant;

selectively expanding the implant between a first, collapsed configuration to facilitate introduction of the implant into the uterus of a patient, and a second, expanded configuration configured to force contact between an outer surface of the implant and the uterus of the patient, each channel of the plurality of channels selectively transitioning between a closed position when the implant is disposed in the first, collapsed configuration and an open position when the implant is disposed in the second, expanded configuration, wherein, upon expansion of the implant against the uterus and the opening of the channels in the second configuration, the bioactive agent is administered through the channels to the uterus; and
separating the implant from the surgical instrument so the surgical instrument can be removed from the patient with the implant maintained within the uterus.

2. The method of claim 1 , wherein introducing the implant adjacent to the endometrium of the uterus includes treating the gynecological malignancy with a chemotherapeutic agent.

3. The method of claim 2 , wherein treating the gynecological malignancy with the chemotherapeutic agent includes treating endometrial cancer, endometrial hyperplasia, endometriosis, or combinations thereof.

4. The method of claim 1 , wherein introducing the implant adjacent to the endometrium of the uterus includes treating the gynecological malignancy with a hormonal agent.

5. The method of claim 4 , wherein treating the gynecological malignancy with the hormonal agent includes treating endometrial cancer, endometrial hyperplasia, endometriosis, or combinations thereof.

6. The method of claim 1 , wherein introducing the implant within the uterus of the patient utilizing the surgical instrument includes transcervically introducing the implant into the uterus.

7. The method of claim 1 , wherein introducing the implant adjacent to the endometrium of the uterus includes inflating the implant with an inflation fluid to conform the implant to a uterine cavity of the uterus of the patient.

8. The method of claim 1 , wherein introducing the implant within the uterus of the patient utilizing the surgical instrument includes introducing at least one IUD within the uterus.

9. The method of claim 1 , wherein introducing the implant within the uterus of the patient utilizing the surgical instrument includes introducing at least one stent within the uterus.

10. An implant system for treating a gynecological malignancy, the system comprising:
a surgical instrument; and
an implant removably coupled to the surgical instrument, the implant selectively expandable between a first, collapsed configuration configured to facilitate introduction into a uterus of a patient, and a second, expanded configuration configured to force contact between an outer surface of the implant and the uterus, the implant including:
a bioactive agent proximate the outer surface of the implant and configured to treat a gynecological malignancy; and
a plurality of channels defined within the outer surface of the implant, each of the channels selectively transitionable between a closed position when the implant is disposed in the first, collapsed configuration and an open position when the implant is disposed in the second, expanded configuration,

wherein the implant is configured to expand into contact with the uterus and when the opening of the channels in the second configuration, and wherein the bioactive agent is configured to be administered through the channels to the uterus.

11. The implant system of claim 10 , wherein the bioactive agent includes a chemotherapeutic agent.

12. The implant system of claim 10 , wherein the bioactive agent includes a hormonal agent.

13. The implant system of claim 10 , wherein at least a portion of the implant includes a bioresorbable material.

14. The implant system of claim, 10 , wherein at least a portion of the implant is semi-permeable.

15. The implant system of claim 10 , wherein the implant is configured to conform to a uterine cavity of the uterus when disposed in the second configuration.

16. The implant system of claim, 10 , wherein the implant is a stent.

17. The implant system of claim, 10 , wherein the implant is an IUD.

Assignees

• Covidien Lp

Inventors

• Begg Nikolai D
• Pickering Chad A
• Whisler Jordan A
• White Rebecca D

Classifications

• A61K9/0039 Primary

  Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception · CPC title

• A61B17/42

  Gynaecological or obstetrical instruments or methods {(ligaturing clamps or clips for the umbilical cord A61B17/122; curettage A61B17/320708)} · CPC title

• A61F6/16

  inflatable · CPC title

• A61F6/18 Primary

  Inserters or removers · CPC title

• A61B2017/4216

  Operations on uterus, e.g. endometrium · CPC title